Detalhe da pesquisa
1.
Prognostic factors for disease activity in newly diagnosed teriflunomide-treated patients with multiple sclerosis: a nationwide Danish study.
J Neurol Neurosurg Psychiatry
; 2024 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38569873
2.
Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: The Early Multiple Sclerosis Exercise Study (EMSES).
Mult Scler
; 28(10): 1620-1629, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35296183
3.
Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study.
Eur J Neurol
; 29(2): 496-504, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34644452
4.
Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry.
Mult Scler
; 27(14): 2254-2266, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33779361
5.
Differences between users and non-users of complementary and alternative medicine among people with multiple sclerosis in Denmark: a comparison of descriptive characteristics.
Scand J Public Health
; 41(5): 492-9, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23548494
6.
Natalizumab treatment of multiple sclerosis - a Danish nationwide study with 13 years of follow-up.
Mult Scler Relat Disord
; 74: 104713, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37058764
7.
Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study.
Mult Scler Relat Disord
; 80: 105127, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37956521
8.
Cannabis-Based Medicine for Neuropathic Pain and Spasticity-A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial.
Pharmaceuticals (Basel)
; 16(8)2023 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37630995
9.
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.
JAMA Neurol
; 80(8): 789-797, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37307006
10.
Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis.
Mult Scler Relat Disord
; 67: 104081, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35944466
11.
Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes.
Mult Scler Relat Disord
; 63: 103892, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35696880
12.
Application of definitions for conversion to secondary progressive MS in a Danish nationwide population.
Mult Scler Relat Disord
; 56: 103319, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34666241
13.
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies.
JAMA Neurol
; 78(10): 1197-1204, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34398221
14.
Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
PLoS One
; 16(5): e0250820, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34003862
15.
Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study.
Neurology
; 95(8): e1041-e1051, 2020 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32636328
16.
Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study.
Neurology
; 92(16): e1811-e1820, 2019 04 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-30877188
17.
High treatment adherence, satisfaction, motivation, and health-related quality of life with fingolimod in patients with relapsing-remitting multiple sclerosis - results from a 24-month, multicenter, open-label Danish study.
Patient Prefer Adherence
; 12: 1139-1150, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29988735
18.
Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark.
Neurology
; 91(24): e2265-e2275, 2018 12 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30413632